Tag: Radical Catheter Technologies

Radical™ Catheter Technologies Announces U.S. FDA 510(k) Clearance for its 6F Neurovascular Catheter — Broadening Access Across a Wide Range of Applications

Radical Catheter Technologies Continues to Expand its Best-in-Class Patented Platform and Scale its Specialized Neurovascular Commercialization Team Radical Catheter Technologies Continues to Expand its Best-in-Class Patented Platform and Scale its Specialized Neurovascular Commercialization Team

Radical Catheter Technologies’ 8F Neurovascular Guide Catheter Demonstrates Outstanding Clinical Performance in Initial Cases

Company to Showcase Progress on Radical Catheter Portfolio and Best-in-Class Ribbon Technology Platform at Society of Neurointerventional Surgery Annual Meeting Company to Showcase Progress on Radical Catheter Portfolio and Best-in-Class Ribbon Technology Platform at Society of Neurointerventional Surgery Annual Meeting

Radical Catheter Technologies’ 8F Neurovascular Catheter Receives US FDA 510(k) Clearance, Second for the Best-in-Class Ribbon Technology Platform

Company Announces New Headquarters, a State-of-the-Art Manufacturing Facility to Expand Commercialization of the Radical Neurovascular Catheter Portfolio to Include a Wide Range of Sizes and Indications Enhancing Efficiency and Precision in Neurosurgery Company Announces New Headquarters, a State-of-the-Art Manufacturing Facility to Expand Commercialization of the Radical Neurovascular Catheter Portfolio to Include a Wide Range of Sizes and Indications Enhancing Efficiency and Precision in Neurosurgery

Radical™ Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery (SNIS) 21st Annual Meeting

Company Simultaneously Announces Close of $20 Million Financing Round, US FDA 510(k) Clearance of Neurovascular Radical Catheter and Initial Post-Market Clinical Experience Company Simultaneously Announces Close of $20 Million Financing Round, US FDA 510(k) Clearance of Neurovascular Radical Catheter and Initial Post-Market Clinical Experience